Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.74
+0.96581.59%
Volume:44.56K
Turnover:2.72M
Market Cap:288.30M
PE:20.19
High:61.83
Open:60.98
Low:60.60
Close:60.77
52wk High:64.10
52wk Low:39.36
Shares:4.67M
Float Shares:4.67M
Volume Ratio:2.21
T/O Rate:0.95%
Dividend:1.53
Dividend Rate:2.47%
EPS(TTM):3.06
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption

Deep News
·
Aug 26

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Reuters
·
Aug 26

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 26

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

Reuters
·
Aug 26

Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares

Reuters
·
Aug 25

Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall

MT Newswires Live
·
Aug 25

Guardant Health to appeal federal district court judgment in TwinStrand case

TIPRANKS
·
Aug 25

Guardant Health, Inc.: Remains Confident That it Did not Infringe Asserted Patents

THOMSON REUTERS
·
Aug 25

Guardant Health, - Current Guardant Reveal and Shield Products Excluded from Final Court Order

THOMSON REUTERS
·
Aug 25

Guardant Health to Appeal Federal District Court Judgment

THOMSON REUTERS
·
Aug 25

U.S. Court Orders Guardant to Pay $245 Million in DNA Sequencing Patent Dispute

Reuters
·
Aug 25